Realizing the clinical potential of ischemic preconditioning and postconditioning

被引:89
作者
Yellon, DM
Hausenloy, DJ
机构
[1] UCL Hosp, Hatter Inst, London WC1E 6DB, England
[2] UCL Hosp, Ctr Cardiol, London WC1E 6DB, England
来源
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE | 2005年 / 2卷 / 11期
关键词
ischemic postconditioning; ischemic preconditioning; kinases; mitochondrial permeability transition pore; reperfusion injury;
D O I
10.1038/ncpcardio0346
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
After an acute myocardial infarction (AMI), early reperfusion by thrombolysis or primary percutaneous coronary intervention remains the mist-effective strategy for limiting the size of an evolving infarct. The mortality from AMI, however remains significant, dsue partly to the lethal reperfusion injury that occurs on reperfusion the ischemic myocardium. Novel cardioprotective strategies are required to target this forum of injury. In ischemic preconditioning transient, nonlethal episodes of myocardial ischemia and reperfusion before the index ischemic preconditioning has not been realized in clinical practice because it necessitates an intervention applied before the onset of AMI, which is difficult to predict. A more-amenable approach to cardioprotection is to intervene at the onset of reperfusion, the timing of which is under the control of the operator. In this regard, ischemic postconditioning, in which transient episodes of myocardial ischemia and reperfusion administered at the onset of reperfusion reduce infarct sixe, constitutes one such intervention. Interestingly, studies suggest that ischemic preconditioning and postconditioning, activate the same signaling pathway at the time of myocardial reperfusion might allow one to harness the cardioprotective potential of ischemic preconditioning and postconditioning. in this review, we discuss the potential application of ischemic preconditioning and postconditioning in the clinical arena of myocardial ischemia and reperfusion, and examine the common signaling pathways by which this might be achieved.
引用
收藏
页码:568 / 575
页数:8
相关论文
共 62 条
[1]   A challenge to the metabolic approach to myocardial ischaemia [J].
Apstein, CS ;
Opie, LH .
EUROPEAN HEART JOURNAL, 2005, 26 (10) :956-959
[2]   Postconditioning inhibits mitochondrial permeability transition [J].
Argaud, L ;
Gateau-Roesch, O ;
Raisky, O ;
Loufouat, J ;
Robert, D ;
Ovize, M .
CIRCULATION, 2005, 111 (02) :194-197
[3]   Na+/H+ exchange inhibitors for cardioprotective therapy:: Progress, problems and prospects [J].
Avkiran, M ;
Marber, MS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) :747-753
[4]   Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway [J].
Bell, RM ;
Yellon, DM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (03) :508-515
[5]   Myocardial protection at a crossroads - The need for translation into clinical therapy [J].
Bolli, R ;
Becker, L ;
Gross, G ;
Mentzer, R ;
Balshaw, D ;
Lathrop, DA .
CIRCULATION RESEARCH, 2004, 95 (02) :125-134
[7]   Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury [J].
Bose, AK ;
Mocanu, MM ;
Carr, RD ;
Brand, CL ;
Yellon, DM .
DIABETES, 2005, 54 (01) :146-151
[8]   MYOCARDIAL REPERFUSION - A DOUBLE-EDGED SWORD [J].
BRAUNWALD, E ;
KLONER, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (05) :1713-1719
[9]   Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo [J].
Bullard, AJ ;
Govewalla, P ;
Yellon, DM .
BASIC RESEARCH IN CARDIOLOGY, 2005, 100 (05) :397-403
[10]   Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: Evidence for anesthetic-induced postconditioning in rabbits [J].
Chiari, PC ;
Bienengraeber, MW ;
Pagel, PS ;
Krolikowski, JG ;
Kersten, JR ;
Warltier, DC .
ANESTHESIOLOGY, 2005, 102 (01) :102-109